Wang Qunbin's Vision for Innovation and Global Expansion at Fosun

Heading for the Future: Wang Qunbin and Fosun's Global Strategy

On October 16, the bustling city of Shanghai hosted the 2025 Sustainability Global Leaders Conference with a compelling theme: "Joining Hands to Address Challenges: Global Action, Innovation, and Sustainable Growth." The event attracted around 500 distinguished guests, including Nobel and Turing Prize laureates, as well as executives from top global companies. One of the key speakers was Wang Qunbin, Co-Chairman of Fosun International, who delivered an inspiring keynote titled "Innovation-Driven Fosun's Path to Global Industry Leadership."

In his address, Wang emphasized the central role of innovation in Fosun's pursuit of globalization and highlighted the importance of balancing business achievements with societal benefits. He stated, "As a global innovation-driven consumer group, Fosun has remained dedicated to our founding principle of 'Contribution to Society' for over three decades. We have harmonized a global outlook with localized operations by integrating technological innovation with social responsibility to pave a sustainable path guided by innovation and accountability."

Addressing Global Health Needs Through Innovation

Wang shared an insightful perspective on the transformative power of innovation in healthcare, asserting, "The greatest innovation is helping people live a life without regrets." He stressed that in medical fields, innovation should not be measured merely by academic statistics, but by the hope it instills in patients' lives. He pointed to HANSIZHUANG, an innovative anti-PD-1 monoclonal antibody developed exclusively by Fosun, as a prime example of its commitment to responding to urgent health needs.

Lung cancer, particularly Small Cell Lung Cancer (SCLC) — the most aggressive subtype — poses significant challenges, with alarmingly high rates of morbidity and mortality. Wang highlighted how Fosun's scientists rose to this challenge, successfully developing HANSIZHUANG, the first anti-PD-1 monoclonal antibody sanctioned for initial SCLC treatment. This groundbreaking treatment has gained approval in nearly 40 countries, supporting over 110,000 patients globally.

Proudly, Wang remarked, "As a Chinese enterprise, we celebrate this approval as a milestone representing the entrance of Chinese pharmaceuticals into the world’s most stringent regulatory markets."

Moreover, Wang noted that just recently, on October 9, HANSIZHUANG met significant clinical milestones in the treatment of gastric cancer, signaling potential changes in how these patients are managed in the future.

Fosun has recorded further advancements in drug development in 2025, including the promising antibody-drug conjugate HLX43, intended for treating solid tumors. This represents a marked shift in Fosun’s trajectory, sometimes described as moving from 'following' to 'leading' in the realm of innovative pharmaceuticals.

Fosun's Global Strategy and Collaboration

With over 30 countries bearing its mark, Fosun has adapted its business model to thrive globally. Wang stated, "We understand that the essence of globalization lies in our innovation capabilities and our capacity to assemble value chains effectively."

In terms of pharmaceutical innovation, Fosun has spent the last decade constructing a strong global presence encompassing research, regulatory approvals, business development, and sales. Their innovative biopharmaceutical products have now reached nearly 60 countries, positively impacting over 850,000 patients. One of their flagship products, HANQUYOU, a monoclonal antibody biosimilar for breast cancer, has made a global impact, gaining approvals across numerous markets.

Global partnerships have been central to Fosun’s strategy—they have established long-term collaborations with prominent firms to expedite market growth. Noteworthy is their impressive surge in cash inflow from business agreements, soaring 280% year-on-year just in the first half of this year, affirming the company’s upward trajectory.

Embracing Innovation Beyond Pharmaceuticals

Fosun's exploration of innovation extends into cultural tourism, with Fosun Tourism Group's Club Med spearheading the use of AI in enhancing guest experiences. Their digital tools have already entered a dozen markets, showcasing how technology can significantly enrich consumer interactions. A collaboration with Alibaba Cloud aims to usher in an intelligent cultural tourism system intended to create more seamless travel experiences.

In the finance sector, Fosun's Insurance arm is leveraging AI to streamline operations and drive growth in its services. Their success in automating processes illustrates how technology is key to redefining traditional business models.

The reach of Chinese culture has expanded too, with events like the Yuyuan Lantern Festival taking center stage in cities worldwide, allowing broader audiences to enjoy and learn about Chinese heritage.

Commitment to Social Responsibility

Wang reiterated that businesses must serve society holistically and stressed that Fosun's innovation endeavors are deeply rooted in their commitment to social good. He recounted how Fosun has made strides in combating malaria through contributions to the production of artemisinin-based drugs, saving millions of lives worldwide.

The initiatives led by Fosun embody its longstanding core value of 'Contribution to Society,' extending from medical aid to grassroots health programs. The Rural Doctors Program, initiated in 2017, has significantly impacted rural healthcare, benefiting millions by supporting local physicians and enhancing healthcare accessibility across underserved areas.

Wang's vision encapsulates not just financial success, but the importance of building a better world through collaborative innovation. As Fosun looks to the future, its commitment to driving innovation and taking on global challenges demonstrates how deeply they understand their role within both the business landscape and the wider community.

As echoes of Wang Qunbin’s impactful speech lingered, it was clear that Fosun International has charted a progressive path, intertwining innovation with societal responsibility to lead as an influential global corporate entity. With such sustained effort and a commitment to excellence, Fosun aims to contribute significantly to a shared global future.